| Ascorbic acid in cancer treatment: let the phoenix fly N Shenoy, E Creagan, T Witzig, M Levine Cancer cell 34 (5), 700-706, 2018 | 183 | 2018 |
| Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome N Shenoy, N Vallumsetla, E Rachmilewitz, A Verma, Y Ginzburg Blood, The Journal of the American Society of Hematology 124 (6), 873-881, 2014 | 148 | 2014 |
| Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting? N Shenoy, R Luchtel, P Gulani BMC medicine 18, 1-6, 2020 | 137 | 2020 |
| miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1 Y Wang, R Lieberman, J Pan, Q Zhang, M Du, P Zhang, M Nevalainen, ... Molecular cancer 15, 1-11, 2016 | 136 | 2016 |
| Scleroderma induced by pembrolizumab: a case series NS Barbosa, DA Wetter, CN Wieland, NK Shenoy, SN Markovic, ... Mayo Clinic Proceedings 92 (7), 1158-1163, 2017 | 109 | 2017 |
| High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model RA Luchtel, T Bhagat, K Pradhan, WR Jacobs Jr, M Levine, A Verma, ... Proceedings of the National Academy of Sciences 117 (3), 1666-1677, 2020 | 102 | 2020 |
| Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm CL Haddox, N Shenoy, KK Shah, JC Kao, S Jain, TR Halfdanarson, ... Annals of Oncology 28 (3), 673-675, 2017 | 99 | 2017 |
| Alterations in the ribosomal machinery in cancer and hematologic disorders N Shenoy, R Kessel, TD Bhagat, S Bhattacharyya, Y Yu, C Mcmahon, ... Journal of hematology & oncology 5, 1-9, 2012 | 99 | 2012 |
| Role of DNA methylation in renal cell carcinoma N Shenoy, N Vallumsetla, Y Zou, JN Galeas, M Shrivastava, C Hu, ... Journal of hematology & oncology 8, 1-13, 2015 | 90 | 2015 |
| Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells N Shenoy, T Bhagat, E Nieves, M Stenson, J Lawson, GS Choudhary, ... Blood cancer journal 7 (7), e587-e587, 2017 | 87 | 2017 |
| Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma N Shenoy, TD Bhagat, J Cheville, C Lohse, S Bhattacharyya, A Tischer, ... The Journal of clinical investigation 129 (4), 1612-1625, 2019 | 75 | 2019 |
| Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival CY Hu, D Mohtat, Y Yu, YA Ko, N Shenoy, S Bhattacharya, MC Izquierdo, ... Clinical Cancer Research 20 (16), 4349-4360, 2014 | 74 | 2014 |
| Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer Y Xia, CC Huang, R Dittmar, M Du, Y Wang, H Liu, N Shenoy, L Wang, ... Oncotarget 7 (24), 35818, 2016 | 73 | 2016 |
| Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective N Shenoy, L Pagliaro Annals of Oncology 27 (9), 1685-1695, 2016 | 70 | 2016 |
| Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer TD Bhagat, Y Zou, S Huang, J Park, MB Palmer, C Hu, W Li, N Shenoy, ... Journal of Biological Chemistry 292 (3), 837-846, 2017 | 57 | 2017 |
| Finasteride and male breast cancer: does the MHRA report show a link? NK Shenoy, SM Prabhakar Journal of cutaneous and aesthetic surgery 3 (2), 102-105, 2010 | 44 | 2010 |
| Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer RK Aggarwal, RA Luchtel, V Machha, A Tischer, Y Zou, K Pradhan, ... Proceedings of the National Academy of Sciences 118 (39), e2106947118, 2021 | 37 | 2021 |
| Targeting chemokine pathways in esophageal adenocarcinoma MS Shrivastava, Z Hussain, O Giricz, N Shenoy, R Polineni, A Maitra, ... Cell cycle 13 (21), 3320-3327, 2014 | 36 | 2014 |
| Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of … SK Barta, Y Zou, J Schindler, N Shenoy, TD Bhagat, U Steidl, A Verma Leukemia & lymphoma 53 (10), 1999-2003, 2012 | 35 | 2012 |
| Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells N Shenoy, M Stenson, J Lawson, J Abeykoon, M Patnaik, X Wu, T Witzig Laboratory Investigation 97 (5), 494-497, 2017 | 34 | 2017 |
